Kantar Health Blog

  • New MOAs in Multiple Myeloma Shine at ASH 2012

    by Stephanie Hawthorne | Dec 10, 2012
    Stephanie Hawthorne
    Oncology Conference Insight Blog from ASH 2012: The multiple myeloma landscape is rapidly evolving, with the recent approval of Kyprolis (carfilzomib, Onyx) and the pending approval of pomalidomide (Celgene), both in the relapsed/refractory setting. We’ll see pivotal data for pomalidomide on Tuesday morning during ASH’s Late-Breaking Abstract session, but the first days of the conference have highlighted a few new mechanisms of action that are showing promising activity in multiple myeloma.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight Blog from SABCS 2012 Adjuvant therapy is improving outcomes in breast cancer and that can always be considered a positive result. Also, those patients who may be ineligible for aromatase inhibitors, will be able to benefit from the new 10-year tamoxifen standard of care. It is clear that long-term follow-up is the key for getting the most out of these adjuvant therapy studies.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight Blog: SABCS 2012 With Afinitor recently approved in combination with hormone therapy and pursuing development in the adjuvant setting, and PD 0332991 now demonstrating highly meaningful clinical activity in ER+ patients, we are at the dawn of a new era in breast cancer that could have significant impact on the future course of the disease.
    Continue Reading > | Go comment! | Share
  • Quality vs. Quantity in Melanoma

    by Stephanie Hawthorne | Oct 2, 2012
    Stephanie Hawthorne
    GSK is looking to challenge Zelboraf (vemurafenib), Roche’s BRAF inhibitor, with its own BRAF targeting molecule, dabrafenib. In addition to BRAF, GSK is looking to make an impact in melanoma with its first-in-class MEK inhibitor, trametinib. ESMO 2012
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    As Sutent is extremely well entrenched as the leader in this setting, it is difficult to believe that the COMPARZ trial, which demonstrated non-inferiority of Votrient results rather than superiority, will have much impact. ESMO 2012
    Continue Reading > | Go comment! | Share
Page